On October 11, 2022 GT Medical Technologies, Inc. reported the enrollment of the first patient into the GESTALT (GammaTile Enhanced Stupp ALTernative Trial) of GammaTile Surgically Targeted Radiation Therapy (STaRT) for patients with newly diagnosed glioblastomas (Press release, GT Medical Technologies, OCT 11, 2022, View Source [SID1234621888]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The GESTALT Clinical Trial will include immediate radiation with GammaTile Therapy followed by the Stupp protocol.

Glioblastoma (GBM) is the most common primary malignant brain tumor in adults, yet effective treatment remains a challenge. In 2005, the Stupp protocol became the standard of care—tumor resection, followed by adjuvant temozolomide (TMZ) and external beam radiation therapy (EBRT) several weeks post-surgery. Unfortunately, patient outcomes remain poor, and there have been few advancements over the last decades.

GammaTile Therapy is the only GBM treatment to be FDA cleared in the past decade and one of only 7 FDA-cleared or -approved GBM treatments in the past 50 years. In clinical trials and patient case studies, GammaTile Therapy provides immediate radiation therapy at the time of surgical resection giving patients an effective treatment alternative for newly diagnosed malignant and recurrent brain tumors of all types.

GammaTiles are radiation implants specifically designed for use in the brain. Each resorbable collagen GammaTile is embedded with Cs-131 radiation sources. The neurosurgeon implants GammaTiles in the cavity created by tumor removal. They begin working immediately to combat residual tumor cells.

The GESTALT Clinical Trial will include immediate radiation with GammaTile Therapy followed by the Stupp protocol. The total radiation administered in this clinical trial with GammaTile Therapy and EBRT will be within standard radiation treatment levels.

"Our goal is to demonstrate how starting radiation immediately at the completion of resection and combining it with the Stupp protocol can improve outcomes," said Matt Likens, president and CEO of GT Medical Technologies. "Since GBM is highly proliferative, approximately 50% of patients experience rapid early progression before they can start the Stupp protocol treatment."

"This is an important study built on sound clinical data with the potential to reshape how we approach glioblastoma treatments in the future. We are pleased to offer this study to our patients at M Health Fairview," commented Dr. Clark Chen, the Lyle French Chair and Head of the Department of Neurosurgery, University of Minnesota Medical School. Dr. Chen played an instrumental role in designing the GESTALT Clinical Trial and leads the GESTALT Clinical Team at this site.

On October 11, 2022 Mission Therapeutics ("Mission"), a drug discovery and development company focused on protein homeostasis by selectively inhibiting deubiquitylating enzymes (DUBs), reported that Dr Paul Wallace, Chief Business Officer, and Dr Suhail Nurbhai, Chief Medical Officer, will attend the 14th Annual Parkinson’s Disease Conference on 13 October 2022 in New York (Press release, Mission Therapeutics, OCT 11, 2022, View Source [SID1234621887]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Parkinson’s Disease Therapeutics Conference is the only conference globally that focuses exclusively on Parkinson’s disease drug development, providing an unmatched platform for industry leaders to share exciting new and unpublished data from the field. Mission will join over 300 research and business professionals in attending poster and speaker presentations.

On October 11, 2022 Mission Therapeutics ("Mission"), a drug discovery and development company focused on protein homeostasis by selectively inhibiting deubiquitylating enzymes (DUBs), reported that its CEO, Anker Lundemose, will attend and present at the 9th Annual Fall Private Company Showcase, co-hosted by Solebury Strategic Communications, BMO and Goodwin, on 13 October 2022 in New York (Press release, Mission Therapeutics, OCT 11, 2022, View Source [SID1234621886]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr Lundemose will be available for one-to-one meetings and will discuss the Company’s business strategy, technology, discovery platform and development programmes in a 20-minute presentation at 11am EDT / 4pm BST.

As well as the company presentations from select private biotechs, the event’s agenda includes two thematic panels, one-to-one meetings with company executives, and a networking reception.

For individuals interested in attending the meeting, please contact the organisers for further information.

On October 11, 2022 ChromaDex Corp. (NASDAQ:CDXC) ("the Company" or "ChromaDex") a global bioscience company dedicated to healthy aging, reported a new long term commercial license and supply agreement with Nestlé Health Science, a global leader in science-based nutritional health solutions (Press release, ChromaDex, OCT 11, 2022, View Source [SID1234621885]). The new agreement expands the previous supply agreement executed in 2018 to include dietary supplements. The agreement provides Nestlé Health Science the non-exclusive right to manufacture, market, distribute, and sell products using nicotinamide riboside or NR, trademarked Niagen, under its brands world-wide, except where ChromaDex has existing exclusive distribution agreements.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Rob Fried, CEO of ChromaDex commented, "Niagen is one of the most important new ingredients to have emerged in decades and we are excited to work with the marketing and science departments of the largest dietary supplement and food company in the world to help take it to the next level."

Approved product categories include medical nutritional, functional food and beverage, and multi-ingredient dietary supplements. Consideration for the rights granted to Nestlé Health Science under the agreement include a $1.975 million initial purchase of Niagen. ChromaDex will also receive certain future commercial milestone payments upon achievement of certain net sales targets and tiered royalties relating to net sales. In conjunction with the agreement, the Company entered into a securities purchase agreement where Nestlé Health Science agreed to purchase 3,816,794 shares of the Company’s common stock, based on the volume weighted average price of the Company’s common stock for the ten trading days preceding October 10, 2022 ($1.31 per share) for gross proceeds of $5 million pursuant to a registered direct offering. The securities purchase agreement contains customary representations, warranties and agreements by the Company and customary conditions to closing.

"We are excited with this opportunity to incorporate the leading booster of nicotinamide adenine dinucleotide (NAD+) into our growing portfolio of science-based consumer health, medical nutrition and supplement products," said Greg Behar, CEO of Nestlé Health Science. "As lifespans increase globally, it’s critical that we find innovative, nutritional solutions to help people stay active and healthy for as long as possible. Niagen is a premium, science backed ingredient that fits perfectly within our portfolio, increasing NAD+ for cellular energy support, so consumers can continue to do the things they love."

ChromaDex’s proprietary ingredient, Niagen, is sold directly to consumers as Tru Niagen, which is backed by clinical and scientific research establishing its safety and efficacy at elevating the coenzyme nicotinamide adenine dinucleotide (NAD+) in humans. NAD+ is an important metabolite involved in virtually every metabolic process in the body, most notably energy metabolism and cell repair.

The registered direct offering described above is being made pursuant to a shelf registration statement the Company filed with the Securities and Exchange Commission, or SEC, on June 12, 2020, which became effective on June 26, 2020 (File No. 333-239144) and a related prospectus supplement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

On October 11, 2022 Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatment of hard to treat cancers, reported the signing of a patent assignment from CLS Therapeutics, Inc. ("CLS") to Xenetic related to Xenetic’s previously announced collaboration with VolitionRx Limited (NYSE AMERICAN:VNRX) ("Volition"), a multi-national epigenetics company, and CLS, a biopharmaceutical company developing first-in-class therapies based on the discovery of novel therapeutic targets (Press release, Xenetic Biosciences, OCT 11, 2022, View Source [SID1234621884]). In consideration of the patent assignment, Xenetic will also issue 850,000 shares of common stock to CLS.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Xenetic Biosciences, Inc., Tuesday, October 11, 2022, Press release picture
"Our team remains intent on driving the DNase technology platform forward with the goal of improving outcomes of existing therapeutic agents in multiple solid tumor indications for which existing therapeutic agents have not been proven to be effective. Our collaboration with Volition and CLS has provided us with research and development partners with expertise and capabilities to help drive the DNase-Armored CAR T program forward. We are excited to continue building on the progress we’ve made thus far and on taking the next steps forward in executing on our plans to advance the DNase technology," commented Jeffrey Eisenberg, Chief Executive Officer of Xenetic.

The Company’s collaboration with Volition is an early exploratory program to evaluate the potential combination of Volition’s Nu.Q technology and Xenetic’s DNase-Armored CAR T platform to develop proprietary adoptive cell therapies potentially targeting multiple types of solid cancers for which current CAR T cell therapies have shown limited or no effect. Under the terms of the collaboration agreement, Volition will fund a research program and the two parties will share proceeds from commercialization or licensing of any products arising from the collaboration.

Epigenetically modified nucleosomes are present on tumor cell surfaces and within the tumor microenvironment of multiple types of solid cancers, and thus these nucleosomes may represent generalizable tumor antigens that are not limited to a single cancer type. Volition’s Nu.Q technology can specifically recognize and target epigenetically modified nucleosomes, while Xenetic’s DNase-Armored CAR T platform is designed to enhance the function of CAR T cells within solid tumor microenvironments.